Xandra Owens Breakefield, PH.D.
|Title||Professor of Neurology|
|Institution||Massachusetts General Hospital|
|Address||Massachusetts General Hospital|
Neurogenetics Unit, CNY 6216
55 Fruit St
Boston MA 02114
Available: 10/01/11, Expires: 10/01/13
The Breakefield laboratory has had a long term focus on glioblastoma (GBM) brain tumors. In the past few years we have shown that tumor cells release microvesicles containing mRNA and miRNA, including retrotransposon human endogenous retrovirus (HERV) sequences. We believe these microvesicles are a means for the tumor to pervert normal cells in their vicinity to support tumor growth. One of the most intact HERV sequences is K113 which retains many properties needed for integration into the genome of host cells. This project would involve using recombinant DNA methods to tag K113 sequences and to transduce GBM cells with this construct to determine whether K113 retrotransposons can be transferred via microvesicles and integrated into the genome of normal cells. We will evaluate the effect of this transfer on growth properties of normal cells in culture and test whether this process occurs in vivo in mouse tumor models. Student will carry out all experiments under supervision of a postdoctoral fellow.
BEAMing PCR Diagnostics of Tumor Exosomes
Summer, 07/06/09 - 09/01/10
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.